Equities research analysts expect that Catalent (NYSE:CTLT) will announce $0.60 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Catalent’s earnings, with estimates ranging from $0.58 to $0.64. Catalent reported earnings per share of $0.65 during the same quarter last year, which suggests a negative year over year growth rate of 7.7%. The company is scheduled to report its next earnings results on Monday, August 27th.

According to Zacks, analysts expect that Catalent will report full year earnings of $1.68 per share for the current year, with EPS estimates ranging from $1.64 to $1.73. For the next year, analysts expect that the firm will post earnings of $1.90 per share, with EPS estimates ranging from $1.72 to $1.97. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Catalent.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, May 1st. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.06. Catalent had a net margin of 2.62% and a return on equity of 21.76%. The firm had revenue of $627.90 million for the quarter, compared to analysts’ expectations of $610.47 million. During the same quarter last year, the company posted $0.38 earnings per share. Catalent’s revenue was up 17.9% on a year-over-year basis.

A number of brokerages have issued reports on CTLT. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a report on Thursday, May 10th. Royal Bank of Canada set a $48.00 target price on shares of Catalent and gave the stock a “buy” rating in a report on Monday, February 5th. Stephens cut shares of Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. UBS raised shares of Catalent from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 21st. Finally, ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $45.67.

In other news, SVP William Downie sold 9,082 shares of Catalent stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $41.80, for a total transaction of $379,627.60. Following the sale, the senior vice president now owns 46,986 shares of the company’s stock, valued at $1,964,014.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.70% of the company’s stock.

Large investors have recently made changes to their positions in the stock. First Bank & Trust raised its holdings in Catalent by 54.2% during the fourth quarter. First Bank & Trust now owns 3,764 shares of the company’s stock worth $155,000 after purchasing an additional 1,323 shares in the last quarter. Point72 Asia Hong Kong Ltd raised its holdings in Catalent by 35,700.0% during the first quarter. Point72 Asia Hong Kong Ltd now owns 3,938 shares of the company’s stock worth $162,000 after purchasing an additional 3,927 shares in the last quarter. CAPROCK Group Inc. bought a new stake in Catalent during the fourth quarter worth approximately $203,000. Quantbot Technologies LP bought a new stake in Catalent during the first quarter worth approximately $229,000. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new stake in Catalent during the fourth quarter worth approximately $242,000.

NYSE CTLT traded up $0.32 during trading hours on Friday, reaching $39.57. The company’s stock had a trading volume of 17,053 shares, compared to its average volume of 869,083. The company has a quick ratio of 1.78, a current ratio of 2.18 and a debt-to-equity ratio of 2.53. Catalent has a 52 week low of $39.10 and a 52 week high of $39.32. The stock has a market capitalization of $5.29 billion, a P/E ratio of 29.30, a P/E/G ratio of 2.11 and a beta of 1.53.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Get a free copy of the Zacks research report on Catalent (CTLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.